Valuation ORIC Pharmaceuticals, Inc. Börse Stuttgart
Stocks
4TZ
US68622P1093
Biotechnology & Medical Research
|
Market Closed -
Börse Stuttgart
15:56:01 2026-10-14 EDT
|
5-day change | 1st Jan Change | ||
| 10.35 EUR | +2.78% |
|
-4.46% | +45.94% |
Company Valuation: ORIC Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 578.9 | 264.8 | 501.9 | 569.5 | 796.6 | 1,201 | - | - |
| Change | - | -54.26% | 89.55% | 13.47% | 39.89% | 50.8% | - | - |
| Enterprise Value (EV) | 578.9 | 264.8 | 266.8 | 569.5 | 751 | 1,201 | 1,201 | 1,201 |
| Change | - | -54.26% | 0.78% | 113.42% | 31.87% | 59.97% | 0% | 0% |
| P/E | -7.1x | -2.62x | -4.69x | -4.41x | -5.56x | -7.64x | -6.85x | -6.02x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.3x | 0.4x | 0.66x | 0.3x | -2.35x | -0.6x | -0.4x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 436x |
| EV / Revenue | - | - | - | - | - | - | - | 436x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -7.44x | -7.26x | -8.4x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -6.71x | -5.75x | -5.05x |
| EV / FCF | -0x | -0x | -0x | -0x | -0x | -8.93x | -7.24x | -5.99x |
| FCF Yield | -10.4% | -29.2% | -17.2% | -20% | -14% | -11.2% | -13.8% | -16.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.07 | -2.25 | -1.96 | -1.83 | -1.47 | -1.518 | -1.691 | -1.927 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 2.757 |
| EBITDA 1 | -77.97 | -90.8 | -109.7 | -141.8 | -141.8 | -161.4 | -165.6 | -143 |
| EBIT 1 | -78.87 | -91.77 | -110.8 | -142.9 | -143 | -179 | -209.1 | -237.8 |
| Net income 1 | -78.72 | -89.12 | -100.7 | -127.8 | -129.5 | -166 | -199.2 | -249.4 |
| Net Debt | - | - | -235 | - | -45.67 | - | - | - |
| Reference price 2 | 14.70 | 5.89 | 9.20 | 8.07 | 8.18 | 11.59 | 11.59 | 11.59 |
| Nbr of stocks (in thousands) | 39,382 | 44,953 | 54,552 | 70,567 | 97,389 | 103,653 | - | - |
| Announcement Date | 3/21/22 | 3/16/23 | 3/11/24 | 2/18/25 | 2/23/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.44x | 7.28x | 14.62x | 1.45% | 70.44B | |
| 27.08x | 7.4x | 23.22x | 0.05% | 50.31B | |
| 33.03x | 5.94x | 17.79x | 0.98% | 47.51B | |
| 33.58x | 3.26x | 14.07x | -.--% | 42.91B | |
| -19.54x | 197.56x | -20.76x | -.--% | 40.39B | |
| 46.24x | 5.25x | 28.83x | -.--% | 39.69B | |
| 26.84x | 7.63x | 19.74x | 0.4% | 30.59B | |
| 30.94x | 6.59x | 17.1x | -.--% | 26.8B | |
| -13.49x | 4.97x | -6x | -.--% | 22.36B | |
| Average | 20.57x | 27.32x | 12.07x | 0.32% | 41.22B | |
| Weighted average by Cap. | 22.12x | 27.00x | 13.15x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ORIC Stock
- 4TZ Stock
- Valuation ORIC Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
